Quantifying the fitness benefit and cost of cefixime resistance in Neisseria gonorrhoeae to inform prescription policy (2017)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1101/121418
Publication URI: http://dx.doi.org/10.1101/121418
Type: Preprint